



232855

00-000000000

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

|      |  | Frequency:   | Expected Length of Therapy:  | Phys<br>Spec<br>Phys<br>gth: | 6/13/2025  Physician Name: Specialty: Physician Office Telephone  th: |   |  |  |
|------|--|--|--|------------------------------|---|---|--|--|
| Con  |  |  |  |                              |   |   |  |  |
| Plea | What is the diagnosis?  Non-24-hour sleep-wa  Nighttime sleep distur | e answer for each applica<br>ake disorder (Non-24) (If che<br>bances in Smith-Magenis sy<br>(If checked, no further ques | ecked, go to 2) yndrome (SMS) (If checked, go to 8)                                    |                              |   |   |  |  |
| 2.   | Is the requested drug pr<br>neurologist experienced<br>psychiatrist? | escribed by or in consultation with sleep disorders, physical  | on with a sleep specialist (e.g., cian certified in sleep medicine) or                 | Y                            |   | N |  |  |
| 3.   | retinas)? ACTION REQUID diagnosis.                                   | diagnosis of total blindness<br>JIRED: If Yes, please attach<br>Submit supporting docume                                 | s in both eyes (e.g., nonfunctioning n chart notes or test results confirming entation | <b>Y</b>                     |   | N |  |  |
| 4.   | Is the patient able to per   | ceive light in either eye?   |  | Y                            |   | N |  |  |
| 5.   | Is the patient currently re  | eceiving therapy with Hetlioz  | z?   | Y                            |   | N |  |  |
| 6.   | duration since starting re<br>supporting documentation               | equested drug? ACTION RE   | sleep and/or decreased daytime nap<br>EQUIRED: If Yes, please attach<br>entation       | Y                            |   | N |  |  |
| 7.   | Is the patient experienci excessive daytime sleep                    | ng difficulty initiating sleep, oiness?  | difficulty awakening in the morning, or  | r Y                          |   | N |  |  |
| 8.   | Is the requested drug pr<br>neurologist experienced<br>psychiatrist? | escribed by or in consultation with sleep disorders, physical  | on with a sleep specialist (e.g., cian certified in sleep medicine) or                 | Y                            |   | N |  |  |
| 9.   | ACTION REQUIRED: If diagnosis.                                       | Yes, please attach chart no  | s of Smith-Magenis syndrome?<br>tes or test results confirming                         | Y                            |   | N |  |  |
| 10.  |  | Submit supporting docume history of sleep disturbance  |  | Y                            |   | N |  |  |
| 11.  | Is the patient currently re  | eceiving therapy with the red  | quested drug?  | Y                            |   | N |  |  |

| 12. | Is the patient experiencing improvement in the quality of sleep such as improvement in sleep efficiency, sleep onset and final sleep offset, or waking after sleep onset since starting therapy? ACTION REQUIRED: If Yes, please attach supporting documentation. ACTION REQUIRED: Submit supporting documentation | Υ | N 🔲 |
|-----|--|---|-----|
|     |  |   |     |

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

## Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.